Tirzepatide Research for Sleep Apnea
An evidence-based overview of research examining Tirzepatide in the context of sleep apnea. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tirzepatide received FDA approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity in December 2024. This is a Zepbound-specific indication. The SURMOUNT-OSA trials demonstrated that tirzepatide significantly reduced the apnea-hypopnea index (AHI) in patients with obesity and OSA. The apnea-hypopnea index is a direct OSA endpoint in these trials; weight loss alone would not establish efficacy for OSA. Zepbound's indication applies in combination with reduced-calorie diet and increased physical activity in adults with obesity, not to all patients with OSA.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.